RxDoctor Payments DataLook up a doctor →

Anjanette Kibby

Family · Chandler, AZNPI 1255091104

Payments from drug & device makers

$20,900in general payments, 2019–2025

Across 697 payments — averaging $29.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Jazz Pharmaceuticals Inc.$2K
  • AstraZeneca$1K
  • Boston Scientific$1K
  • UCB, Inc.$1K
  • Argenx US, Inc.$777
  • plus $12K from 54 others

What the payments were for

  • Consulting fees$1501%
  • Speaking & faculty fees$200%
  • Travel & lodging$8894%
  • Food & beverage$19,12091%
  • Education$7213%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie169$3,123
Jazz Pharmaceuticals Inc.30$1,818
AstraZeneca(2 entities)26$1,120
Boston Scientific6$1,117
UCB, Inc.46$1,053
Argenx US, Inc.34$777
Eisai Inc.24$760
Pfizer45$753
Livanova USA, Inc.5$747
Otsuka America Pharmaceutical, Inc.13$673
Biogen25$664
Lundbeck LLC21$580
Neurocrine Biosciences, Inc.14$522
Neurelis, Inc.15$507
Sanofi6$469
Lilly USA, LLC14$417
EMD Serono, Inc.10$379
Avadel CNS Pharmaceuticals, LLC10$370
Novartis17$331
Biohaven Pharmaceutical Holding Company Ltd.5$286
Johnson & Johnson3$265
C2n Diagnostics, LLC18$263
Grifols USA, LLC7$261
CSL Behring8$252
Axsome Therapeutics, Inc.3$249
Bristol Myers Squibb13$213
Acorda Therapeutics, Inc16$208
Amgen(2 entities)7$203
Teva Pharmaceuticals USA, Inc.8$189
Medtronic2$186
Averitas Pharma Inc.3$166
Harmony Biosciences LLC6$149
Genentech USA, Inc.5$145
MDD US Operations, LLC4$145
Alnylam Pharmaceuticals Inc.5$139
Amneal Pharmaceuticals LLC6$128
E.r. Squibb & Sons, L.L.C.1$125
Idorsia Pharmaceuticals US Inc1$112
ANI Pharmaceuticals, Inc.3$102
Acadia Pharmaceuticals Inc5$101
Merz Pharmaceuticals, LLC3$88
Sandoz3$73
Insightec,inc1$61
Scilex Pharmaceuticals Inc.3$61
Upsher-smith Laboratories LLC3$59
TG Therapeutics, Inc.2$43
Avion Pharmaceuticals2$41
Kyowa Kirin, Inc.2$39
Sumitomo Pharma America, Inc.3$39
Springworks Therapeutics, Inc.1$33
Cala Health, Inc.1$32
Mallinckrodt Hospital Products Inc.1$26
Sunovion Pharmaceuticals Inc.2$25
Tanabe Pharma America, Inc.1$25
Impel Pharmaceuticals Inc.1$25
Otto Bock Healthcare LP1$24
Corium, LLC1$22
Noctrix Health, Inc.1$22
GE HealthCare1$21
Banner Life Sciences, LLC1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,900 in reported general payments places this provider in the 95th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$115,334
Medicare patients
558
Services billed
1,652

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UltomirisRavulizumab-Cwvz21$1,192,553
IngrezzaValbenazine Tosylate22$180,111
NuplazidPimavanserin Tartrate35$169,094
VumerityDiroximel Fumarate11$109,369
RexultiBrexpiprazole26$40,386
Nurtec OdtRimegepant Sulfate17$33,039
RytaryCarbidopa/Levodopa22$26,820
Lacosamide97$25,328
UbrelvyUbrogepant12$19,313
Emgality PenGalcanezumab-Gnlm17$15,649
Memantine Hcl445$14,835
Carbidopa-LevodopaCarbidopa/Levodopa314$8,981
Entacapone47$7,992
Levetiracetam119$6,117
Gabapentin214$6,021

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaUltomiris$1,120$1,192,55321 claims
Neurocrine Biosciences, Inc.Ingrezza$522$180,11122 claims
Acadia Pharmaceuticals IncNuplazid$101$169,09435 claims
BiogenVumerity$664$109,36911 claims
Otsuka America Pharmaceutical, Inc.Rexulti$673$40,38626 claims
PfizerNurtec Odt$753$33,03917 claims
Amneal Pharmaceuticals LLCRytary$128$26,82022 claims
AbbVieUbrelvy$3,123$19,31312 claims
Upsher-smith Laboratories LLCTopiramate$59$1,24169 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,119 family providers in Arizona.

Other family in Chandler

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →